Drugs / Recombinant Human Proteoglycan 4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07118241 | Sep 2025 → Jul 2026 overdue | Sjogren syndrome | Lubris Bio Pty Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Human Proteoglycan 4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07118241 ↗ |
| Route | Topical | “topically-applied rhPRG4” NCT07118241 ↗ |